hif2alpha inhibitor dff332
Generic: HIF2alpha Inhibitor DFF332
hif2alpha inhibitor dff332: 1 clinical trial tracked.
hif2alpha inhibitor dff332 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about hif2alpha inhibitor dff332, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Interventionalopen40 targetStarted 2021-11Completion 2026-0211 sites · Czechia, France, Italy, Japan…Novartis Pharmaceuticals